
    
      This is a Phase 2a, multi-center, multiple dose study in subjects with Neovascular
      Age-related Macular Degeneration (nAMD) to investigate the safety and tolerability of GEM103
      IVT injection + standard of care vs. sham + standard of care.

      Subjects will undergo clinical and ophthalmic assessments for determination of inclusion in
      the study and who meet all eligibility criteria will be enrolled.
    
  